Innovent Biologics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Innovent Biologics, Inc.'s yearly results (2022–2025), compared with companies in China. Tap ? on any ratio for what it means.
What stands out
- Shareholder Slice Ratio: Share count rose 13% in 3 years, so each share's slice of the company became smaller. Bigger rise in share count than 97% of companies in China.
- Steadiness Ratio: Sales and profit both grew in each of the last 3 years. Steadier than 86% of companies in China.
- Debt Due Cover Ratio: Debt due within a year is covered 12.7 times by its yearly operating cash. Higher than 85% of companies in China.
Where ¥100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
3.0×Over the last 3 years its own operating cash covered its investment spending (capex) 3.0 times.
Higher than 63% of companies in China.
Cash Locked Ratio
¥11For every ¥100 of sales, ¥11 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ¥23 tied up three years earlier.
More money tied up than 75% of companies in China.
Growth quality
Steadiness Ratio
3/3 · 3/3Sales and profit both grew in each of the last 3 years.
Steadier than 86% of companies in China.
Growth Efficiency Ratio
¥35Sales grew 186% in 3 years; of every extra ¥100 of sales, ¥35 became extra profit.
Higher than 75% of companies in China.
Asset Productivity Ratio
+186% / +112%In 3 years sales changed by +186% while total assets changed by +112%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
12.7×Debt due within a year is covered 12.7 times by its yearly operating cash.
Higher than 85% of companies in China.
Cash Cushion Ratio
—Data incomplete
Tangible Assets Ratio
95%Of every ¥100 the company owns, ¥95 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 63% of companies in China.
Tangible Net Worth Ratio
90%Of every ¥100 of net worth, ¥90 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
Less tangible than 62% of companies in China.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
Innovent Biologics, Inc. owes ¥0.48 for every ¥1 it owns. Innovent Biologics, Inc. returned to profit in the year to Dec 2025, after a loss the year before.
Compared with companies in China · latest annual results Dec 2025.
P/E ratio
116.6Investors pay ¥116.6 for every ¥1 of Innovent Biologics, Inc.'s yearly profit, higher than 97% of companies in China.
P/B ratio
6.25The share price is 6.25 times Innovent Biologics, Inc.'s book value per share, higher than 96% of companies in China.
Market cap
HK$142.3 BThe total market value of all of Innovent Biologics, Inc.'s shares at today's price (share price × number of shares), smaller than 59% of companies in China. PosiCap size class: Tito Cap.
Net worth (book value)
¥19.4 BWhat Innovent Biologics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Dec 2025).
Return on equity (ROE)
7.0%Innovent Biologics, Inc. earned 7.0% on its shareholders' money over the last year, lower than 73% of companies in China.
Owes vs Owns
0.48×Innovent Biologics, Inc. owes ¥0.48 for every ¥1 it owns (low), lower than 52% of companies in China.
Dividend yield
NoneInnovent Biologics, Inc. does not currently pay a dividend.
Revenue growth
+38%Revenue rose 38% in the year to Dec 2025, and grew 42% a year on average over 3 years.
Profit growth
Back to profitInnovent Biologics, Inc. returned to profit in the year to Dec 2025, after a loss the year before.
Profit margin
6.2%Innovent Biologics, Inc. keeps ¥6 of every ¥100 of revenue as net profit.
Cash quality
12.3×Cash from Innovent Biologics, Inc.'s business was 12.3× its reported profit in the year to Dec 2025 — its profit turned into cash.
Interest cover
26.9×Innovent Biologics, Inc.'s operating profit covered its interest costs 26.9 times in the year to Dec 2025.
Cash vs debt
Net cashInnovent Biologics, Inc. held ¥15.4 B more cash than debt (net cash) at Dec 2025.
Questions
What is Innovent Biologics, Inc.'s P/E ratio?
Investors pay ¥116.6 for every ¥1 of Innovent Biologics, Inc.'s yearly profit, higher than 97% of companies in China.
What is Innovent Biologics, Inc.'s return on equity?
Innovent Biologics, Inc. earned 7.0% on its shareholders' money over the last year, lower than 73% of companies in China.
How much does Innovent Biologics, Inc. owe compared with what it owns?
Innovent Biologics, Inc. owes ¥0.48 for every ¥1 it owns (low), lower than 52% of companies in China.
Does Innovent Biologics, Inc. pay a dividend?
No. Innovent Biologics, Inc. does not currently pay a dividend.
Is Innovent Biologics, Inc.'s revenue growing?
Revenue rose 38% in the year to Dec 2025, and grew 42% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.